Leptomeningeal Metastases (LM) is a devastating complication of advanced cancers, where cancer cells spread to the cerebrospinal fluid and leptomeninges of the brain and spinal cord. Research and collaboration are critical to improving outcomes for patients facing this challenging diagnosis.
On August 14 at 6:15 PM, several of the top experts in leptomeningeal metastases will join a presentation and panel discussion at the SNO/ASCO CNS Metastases Conference in Baltimore.
Learn more about the presentation here.
Why This Session Matters
Leptomeningeal metastases (LM) remains an area of high unmet medical need with limited treatment options and poor prognosis. By bringing together top LM experts, this conference session aims to:
-
Share the latest research and clinical trial updates
-
Discuss diagnostic and therapeutic advances
-
Highlight new collaborations advancing LM treatment
Plus Therapeutics’ Role in LM Research
At Plus Therapeutics, we are dedicated to developing innovative therapies for central nervous system cancers, including leptomeningeal metastases. Presenting at the ASCO/SNO CNS Metastases Conference underscores our commitment to advancing treatment options for patients with some of the most difficult-to-treat cancers.
Join the Conversation
This conference session provides an important platform for collaboration, innovation, and hope in the fight against leptomeningeal metastases.
Follow Plus Therapeutics for updates on our research programs and clinical trials.
#LeptomeningealMetastases #LM #NeuroOncology #BrainCancer #CNSMetastases #CancerResearch #ClinicalTrials #OncologyInnovation #ASCO #SNO #PlusTherapeutics #PSTV #CNSideDiagnostics
Recent Comments